Literature DB >> 16730130

N-acetylaspartate as a reservoir for glutamate.

Joseph F Clark1, Amos Doepke, Jessica A Filosa, Robert L Wardle, Aigang Lu, Timothy J Meeker, Gail J Pyne-Geithman.   

Abstract

N-acetylaspartate (NAA) is an intermediary metabolite that is found in relatively high concentrations in the human brain. More specifically, NAA is so concentrated in the neurons that it generates one of the most visible peaks in nuclear magnetic resonance (NMR) spectra, thus allowing NAA to serve as "a neuronal marker". However, to date there is no generally accepted physiological (primary) role for NAA. Another molecule that is found at similar concentrations in the brain is glutamate. Glutamate is an amino acid and neurotransmitter with numerous functions in the brain. We propose that NAA, a six-carbon amino acid derivative, is converted to glutamate (five carbons) in an energetically favorable set of reactions. This set of reactions starts when aspartoacylase converts the six carbons of NAA to aspartate and acetate, which are subsequently converted to oxaloacetate and acetyl CoA, respectively. Aspartylacylase is found in astrocytes and oligodendrocytes. In the mitochondria, oxaloacetate and acetyl CoA are combined to form citrate. Requiring two steps, the citrate is oxidized in the Kreb's cycle to alpha-ketoglutarate, producing NADH. Finally, alpha-ketoglutarate is readily converted to glutamate by transaminating the alpha-keto to an amine. The resulting glutamate can be used by multiple cells types to provide optimal brain functional and structural needs. Thus, the abundant NAA in neuronal tissue can serve as a large reservoir for replenishing glutamate in times of rapid or dynamic signaling demands and stress. This is beneficial in that proper levels of glutamate serve critical functions for neurons, astrocytes, and oligodendrocytes including their survival. In conclusion, we hypothesize that NAA conversion to glutamate is a logical and favorable use of this highly concentrated metabolite. It is important for normal brain function because of the brain's relatively unique metabolic demands and metabolite fluxes. Knowing that NAA is converted to glutamate will be important for better understanding myriad neurodegenerative diseases such as Canavan's Disease and Multiple Sclerosis, to name a few. Future studies to demonstrate the chemical, metabolic and pathological links between NAA and glutamate will support this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16730130     DOI: 10.1016/j.mehy.2006.02.047

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  39 in total

1.  Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.

Authors:  Tatsunobu Natsubori; Hideyuki Inoue; Osamu Abe; Yosuke Takano; Norichika Iwashiro; Yuta Aoki; Shinsuke Koike; Noriaki Yahata; Masaki Katsura; Wataru Gonoi; Hiroki Sasaki; Hidemasa Takao; Kiyoto Kasai; Hidenori Yamasue
Journal:  Schizophr Bull       Date:  2013-09-10       Impact factor: 9.306

Review 2.  N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.

Authors:  John R Moffett; Brian Ross; Peethambaran Arun; Chikkathur N Madhavarao; Aryan M A Namboodiri
Journal:  Prog Neurobiol       Date:  2007-01-05       Impact factor: 11.685

3.  Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy.

Authors:  Fawzi Boumezbeur; Graeme F Mason; Robin A de Graaf; Kevin L Behar; Gary W Cline; Gerald I Shulman; Douglas L Rothman; Kitt F Petersen
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-30       Impact factor: 6.200

4.  Regional decoupling of N-acetyl-aspartate and glutamate in schizophrenia.

Authors:  Nina V Kraguljac; Meredith A Reid; David M White; Jan den Hollander; Adrienne C Lahti
Journal:  Neuropsychopharmacology       Date:  2012-07-18       Impact factor: 7.853

5.  Enhanced brain distribution of modified aspartoacylase.

Authors:  Nitesh K Poddar; Stephen Zano; Reka Natarajan; Bryan Yamamoto; Ronald E Viola
Journal:  Mol Genet Metab       Date:  2014-07-12       Impact factor: 4.797

6.  Metabolism changes during aging in the hippocampus and striatum of glud1 (glutamate dehydrogenase 1) transgenic mice.

Authors:  In-Young Choi; Phil Lee; Wen-Tung Wang; Dongwei Hui; Xinkun Wang; William M Brooks; Elias K Michaelis
Journal:  Neurochem Res       Date:  2014-01-21       Impact factor: 3.996

7.  Structure of aspartoacylase, the brain enzyme impaired in Canavan disease.

Authors:  Eduard Bitto; Craig A Bingman; Gary E Wesenberg; Jason G McCoy; George N Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-28       Impact factor: 11.205

8.  Update on the neurobiology of schizophrenia: a role for extracellular microdomains.

Authors:  D Shan; S Yates; R C Roberts; R E McCullumsmith
Journal:  Minerva Psichiatr       Date:  2012-09-01

9.  Decoupling of N-acetyl-aspartate and glutamate within the dorsolateral prefrontal cortex in schizophrenia.

Authors:  J M Coughlin; T Tanaka; A Marsman; H Wang; S Bonekamp; P K Kim; C Higgs; M Varvaris; R A E Edden; M Pomper; D Schretlen; P B Barker; A Sawa
Journal:  Curr Mol Med       Date:  2015       Impact factor: 2.222

10.  N-acetylaspartate normalization in bipolar depression after lamotrigine treatment.

Authors:  Paul E Croarkin; M Albert Thomas; John D Port; Joshua M Baruth; Doo-Sup Choi; Osama A Abulseoud; Mark A Frye
Journal:  Bipolar Disord       Date:  2014-12-12       Impact factor: 6.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.